on BioNxt Solutions Inc. (CVE:BNXT)
BioNxt Progresses with Semaglutide Oral Film Program
BioNxt Solutions Inc. has successfully completed proof-of-concept trials for its Semaglutide oral dissolvable film (ODF) at its subsidiary, Vektor Pharma in Germany. Among several evaluated proprietary film platforms, one displayed promising results, leading to the creation of Semaglutide-ODF prototypes with impressive characteristics such as rapid disintegration and good manufacturing feasibility.
These developments underscore the technology's suitability for complex peptide formulations, propelling BioNxt's program into its next developmental stage. The company plans to file a patent and optimize formulation, aiming for preclinical tests by 2026.
Semaglutide, known under brands like Ozempic® and Rybelsus®, is gaining global traction in the GLP-1 market, a trend BioNxt aims to leverage with its non-invasive delivery alternative.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioNxt Solutions Inc. news